Salud financiera de hoja de balance de Evolva Holding

Salud financiera controles de criterios 5/6

Evolva Holding tiene un patrimonio de accionistas total de CHF5.6M y una deuda total de CHF0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CHF9.8M y CHF4.3M respectivamente. El BAIT de Evolva Holding es de CHF506.2K, por lo que su ratio de cobertura de intereses es de 0.4. Tiene efectivo e inversiones a corto plazo que ascienden a CHF5.8M.

Información clave

Ratio deuda-patrimonio

CHF0

Deuda

Ratio de cobertura de intereses	0.4x
Efectivo	CHF5.84m
Patrimonio	CHF5.55m
Total pasivo	CHF4.28m
Activos totales	CHF9.83m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of Debt

Nov 21

Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?

Jun 09

Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A Catch

May 05

Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?

Mar 22

Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?

Dec 01

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Apr 01

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Feb 13

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Dec 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CHF9.8M) de EVE superan a sus pasivos a corto plazo (CHF2.7M).

Pasivo a largo plazo: Los activos a corto plazo de EVE (CHF9.8M) superan a sus pasivos a largo plazo (CHF1.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: EVE está libre de deudas.

Reducción de la deuda: EVE no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: EVE tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: EVE tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 14.1% cada año.

Salud financiera de hoja de balance de Evolva Holding

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Evolva Holding SA ADR - Sponsored to Be Deleted from OTC Equity

Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss Exchange

We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of Debt

Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?

Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?

Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?

Recent updates

Evolva Holding SA, Annual General Meeting, Apr 12, 2024

Evolva Holding SA ADR - Sponsored to Be Deleted from OTC Equity

Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss Exchange

Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.

New major risk - Market cap size

We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of Debt

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Evolva Receives Approval for Veri-Te Resveratrol in Thailand

Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan

Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?

Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A Catch

Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)

No independent directors

First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)

Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025

Evolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023

Evolva Holding SA announced that it has received CHF 6.3226 million in funding

Evolva Holding SA Announces Management Appointments

Price target decreased to CHF0.21

No independent directors

Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Price target decreased to CHF0.23

Full year 2021 earnings: EPS and revenues miss analyst expectations

Evolva Holding SA Announces Executive Changes

Forecast to breakeven in 2023

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?

First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)

Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SA

Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time Being

Chief Financial Officer has left the company

Price target raised to CHF0.32

Earnings beat expectations, revenue disappoints

Evolva Announces Management Changes

Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)

Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their Shares

Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing Sugar

New 90-day high: CHF0.24

We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn Rate

Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021

New 90-day low: CHF0.23

Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating Officer

Analysts update estimates

Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day high - CHF0.31

Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera